Ebun Garner, the General Counsel & Corp. Sec. of $ERAS, sold 120,000 shares of the company on 01-07-2026 for an estimated $670,812. We received data on the trade from a recent SEC filing. This was a sale of approximately 82.7% of their shares of this class of stock. Following this trade, they now own 25,076 shares of this class of $ERAS stock.
$ERAS Insider Trading Activity
$ERAS insiders have traded $ERAS stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $ERAS stock by insiders over the last 6 months:
- EBUN GARNER (General Counsel & Corp. Sec.) sold 120,000 shares for an estimated $670,812
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ERAS Hedge Fund Activity
We have seen 60 institutional investors add shares of $ERAS stock to their portfolio, and 58 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VIVO CAPITAL, LLC added 2,516,672 shares (+37.2%) to their portfolio in Q3 2025, for an estimated $5,486,344
- PARADIGM BIOCAPITAL ADVISORS LP added 1,652,835 shares (+13.9%) to their portfolio in Q3 2025, for an estimated $3,603,180
- MARSHALL WACE, LLP removed 1,548,416 shares (-74.6%) from their portfolio in Q3 2025, for an estimated $3,375,546
- SILVERARC CAPITAL MANAGEMENT, LLC removed 1,201,516 shares (-46.8%) from their portfolio in Q3 2025, for an estimated $2,619,304
- PFM HEALTH SCIENCES, LP removed 1,072,224 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $2,337,448
- MILLENNIUM MANAGEMENT LLC removed 883,168 shares (-23.3%) from their portfolio in Q3 2025, for an estimated $1,925,306
- JAIN GLOBAL LLC removed 774,340 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,688,061
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ERAS Analyst Ratings
Wall Street analysts have issued reports on $ERAS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 11/14/2025
- Stifel issued a "Buy" rating on 10/16/2025
- B of A Securities issued a "Underperform" rating on 09/03/2025
To track analyst ratings and price targets for $ERAS, check out Quiver Quantitative's $ERAS forecast page.
$ERAS Price Targets
Multiple analysts have issued price targets for $ERAS recently. We have seen 6 analysts offer price targets for $ERAS in the last 6 months, with a median target of $4.5.
Here are some recent targets:
- Kelsey Goodwin from Piper Sandler set a target price of $5.0 on 01/07/2026
- Graig Suvannavejh from Mizuho set a target price of $5.0 on 12/09/2025
- Michael Schmitz from Guggenheim set a target price of $5.0 on 11/14/2025
- Laura Prendergast from Stifel set a target price of $4.0 on 10/16/2025
- Alec Stranahan from B of A Securities set a target price of $1.0 on 09/03/2025
- Jeffrey Hung from Morgan Stanley set a target price of $2.0 on 08/18/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
